Status:
COMPLETED
Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Lesions
Multiple Sclerosis
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
It is difficult to determinate prognostic criteria of Multiple Sclerosis with conventional MRI insofar as physiopathology is not well-known: the precise sequences of events leading to plaque formation...
Detailed Description
The objective of this work are: * study weakly development of the active MS plaque with multimodal MRI parameters using advanced MRI techniques: Veinography/3D FLAIR, Diffusion (CDA), Perfusion (CBV,...
Eligibility Criteria
Inclusion
- Age between 18 and 50 years.
- Health coverage.
- Any form of MS defined by Mc Donald's criteria (2005).
- Patients having shown an enhanced plaque on a less than six month MRI examination.
Exclusion
- Patients with an immunomodulating therapy like natalizumab (Tysabri) and intravenous immunosuppressive therapies. Other therapies will not be excluded from this study. For patients treated by systemic corticotherapy, a one-month delay will be necessary before a MRI examination.
- Cerebral microangiopathy (diabetes, arterial hypertension, vascularitis…)
- Patient with classical MRI contraindication like pace-maker, cardiac valvulosis, claustrophobia, allergy to contrast agent …
- Pregnancy or pregnancy desire.
- Patient with a low creatinine clearance \<60 ml/mn
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00861172
Start Date
February 1 2009
End Date
July 1 2012
Last Update
June 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Services de Neurologie A et Service de Neuroradiologie, Pôle transversal d'imagerie, Hôpital Neurologique
Bron, France, 69677